To include your compound in the COVID-19 Resource Center, submit it here.

CEE 03-310: Began Phase II trial

CeNeS Pharmaceuticals plc (LSE:CEN), Cambridge, U.K.

Read the full 65 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE